Skip to main content

Table 4 The domains SF-12 questionnaire at the beginning and after 12 weeks of intervention in people with polycystic ovary syndrome

From: Synbiotic as an ameliorating factor in the health-related quality of life in women with polycystic ovary syndrome. A randomized, triple-blind, placebo-controlled trial

Variables

Intervention group N = 28

Control group N = 24

95% CI

P**

P***

Lower

Upper

Physical score

      

 Baseline

 End of trial

 Change

66.75 ± 12.61

68.95 ± 14.23

2.19 ± 10.79

65.54 ± 17.94

73.07 ± 18.91

7.53 ± 18.02

-7.33

-13.36

-13.47

9.76

5.12

2.80

0.777

0.375

0.194

 

 P*

0.291

0.052

    

Mental score

      

 Baseline

 End of trial

 Change

55.06 ± 13.31

55.00 ± 15.72

-0.37 ± 13.96

54.72 ± 18.17

59.16 ± 19.29

4.44 ± 13.92

-8.55

-13.92

-12.67

9.23

5.58

3.04

0.939

0.395

0.224

 

 P*

0.891

0.132

    

Cronbach’s alpha

      

 Baseline

 End of trial

0.806

0.882

0.903

0.940

    
  1. P*: p-values for comparison within groups via paired t-test.
  2. P**: p-values for comparison between groups via independent t-test.
  3. P***: p-values based on an ANCOVA model adjusted with baseline value of the outcome, age, marital status, PCOS duration and mean changes in BMI, waist circumference and hip circumference.
  4. CI: confidence interval
Back to article page

BMC Women's Health

ISSN: 1472-6874

Contact us